Filters
After months of work disruption, profound worrying, social distancing, and isolation, SARS-CoV-2* still rages on, unyielding to human interventions.
Use of the interleukin(IL)-1 inhibitor anakinra led to clinical improvements in patients with coronavirus disease (COVID)-19, acute respiratory distress syndrome (ARDS), and systemic inflammation who are under noninvasive ventilation outside the intensive care unit (ICU), an Italian retrospective study has shown.
Majority of patients with confirmed SARS-CoV-2 infections appear to be capable of mounting an immunoglobulin (Ig) G immune response to the disease, according to a new pre-print.
A number of patients with coronavirus disease 2019 (COVID-19) present with diarrhoea, and this group may suffer discomfort longer and show persistent positive SARS-CoV-2 in stool specimens as compared with patients who do not have the symptom, as shown in a study.
The incidence of thromboembolic events in patients with the novel coronavirus disease (COVID-19) is surprisingly high, which suggests a significant role of COVID-19–induced coagulopathy, according to the results of a prospective cohort study in Germany.
One in five men seeking medical help for a couple’s primary infertility have asymptomatic semen infections, which contribute to impaired sperm concentration, a study has found.
Infection with Helicobacter pylori is inversely associated with long-segment Barrett’s oesophagus (LSBE) but is significantly correlated with short-segment (SS)BE in individuals without reflux esophagitis, according to a recent study in a Japanese population.
At present, there are no definitive treatments for COVID-19. More than 300 clinical trials are ongoing in the search for a cure. Some of the treatments being tested were previously used, with varying levels of efficacy, in the treatment of severe acute respiratory syndrome (SARS) or Middle East respiratory syndrome (MERS).
The coronavirus disease 2019 (COVID-19) appears to be most transmissible during the early stages of the disease, or even before symptom onset, according to a recent study.
Hydroxychloroquine appears to have more potent in vitro anti-SARS-CoV-2 activity than chloroquine, as shown in a study.
